• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall

cafead

Administrator
Staff member
  • cafead   Sep 19, 2022 at 10:12: PM
via After rumors of stalled buyout talks between Merck and Seagen, perhaps a new Tukysa indication could reignite interest.

The FDA has granted Tukysa a priority review in combination with Genentech’s Herceptin for second-line HER2-positive metastatic colorectal cancer, the company revealed on Monday.

article source
 

<